Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Nu T., Raizer, Jeffrey, Gabor, Erwin P., Liu, Natalie M., Vu, James Q., Slamon, Dennis J., Barstis, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570757/
https://www.ncbi.nlm.nih.gov/pubmed/26380087
http://dx.doi.org/10.1186/s40425-015-0084-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570757/
https://www.ncbi.nlm.nih.gov/pubmed/26380087
http://dx.doi.org/10.1186/s40425-015-0084-y

Ejemplares similares